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Abstract
Carcinoids are the most common neuroendocrine tumours. They are usually slowly growing, located in the small intestine, secrete seroto-
nin, and are characterized by long survival of patients, so prognosis is generally good. The most frequently encountered clinical presenta-
tions of carcinoids are intermittent abdominal pain and carcinoid syndrome (diarrhoea and flushing). Metastases worsen the prognosis
and limit the survival of the patients. We report a case of carcinoid tumour with primary focus in the ileum, with an appendix infiltration,
in a thirty-two-year-old woman with acute appendicitis symptoms only. Carcinoid was diagnosed postoperatively by histopathological
examination. Nowadays, twenty-five years after the surgery, there is evidence of nearly asymptomatic numerous metastases. Only inter-
mittent abdominal pain for about 1–2 years was reported. Partial metastases resection was performed, followed by chemotherapy,
90Y-DOTATATE and then long-acting release octreotide analogue therapy. In the meantime, severe chronic heart failure (NYHA IV) due to
tricuspid combined valvular heart disease and pulmonary hypertension was diagnosed. Combined therapy, typical for chronic heart
failure, together with long-acting octreotide analogue highly improved the patient’s heart sufficiency and reduced carcinoid syndrome
symptoms. The only adverse events of octreotide therapy were hyperbilirubinaemia and itching. Long-term survival is typical for carcino-
ids, but 30-years survival has not been described in the literature yet.  (Pol J Endocrinol 2009; 60 (5): 401–406)
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Streszczenie
Rakowiak jest jednym z najczęstszych guzów neuroendokrynnych. Umiejscawia się w obrębie jelita cienkiego, zazwyczaj jako wolno
rosnący guz wydzielający serotoninę. Pacjentów chorych na rakowiaka charakteryzuje długie przeżycie i dobre w większości przypad-
ków rokowanie. Najczęstszymi objawami tego nowotworu są nawracające bóle w jamie brzusznej i objawy zespołu rakowiaka (biegunka
i napadowe zaczerwienienia skóry — „flush”). Pojawienie się przerzutów pogarsza rokowanie oraz skraca czas przeżycia chorych. Opisa-
ny przypadek dotyczy 32-letniej kobiety z pierwotnym ogniskiem rakowiaka zlokalizowanym w jelicie krętym, naciekajacym wyrostek
robaczkowy z objawami ostrego zapalenia wyrostka robaczkowego. Rakowiak został zdiagnozowany pooperacyjnie na podstawie oceny
histopatologicznej. Dwadzieścia pięć lat po zabiegu operacyjnym wykryto prawie bezobjawowe liczne ogniska przerzutowe. Chora
w wywiadzie wymieniła jedynie nawracające bóle w jamie brzusznej w okresie 1–2 lat przed rozpoznaniem przerzutów. W trakcie zabiegu
operacyjnego usunięto część guzów przerzutowych, a następnie poddano pacjentkę chemioterapii, leczeniu 90Y-DOTATATE, a następnie
preparatami oktreotydu LAR. W międzyczasie rozpoznano przewlekłą, ciężką niewydolność serca (NYHA IV) w przebiegu złożonej
wady zastawki trójdzielnej serca oraz nadciśnienia płucnego. Złożona terapia, typowa dla przewlekłej niewydolności serca razem z dłu-
godziałającym analogiem oktreotydu znacznie poprawiły wydolność serca oraz zredukowały objawy zespołu rakowiaka. Jedynym dzia-
łaniem niepożądanym terapii oktreotydem były hiperbilirubinemia oraz świąd. Długi okres przeżycia jest typowy dla rakowiaka, jednak
30-letnie przeżycie nie było dotychczas opisywane w literaturze. (Endokrynol Pol 2009; 60 (5): 401–406)
Słowa kluczowe: rakowiak, oktreotyd, przewlekła niewydolność serca
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Introduction
Neuroendocrine tumours (NETs) are typically located
in the small intestine, predominantly in the ileum. The-
ir incidence is not differentiated between sexes and va-
ries from 2.8 to 8.0 cases per 100 000. Carcinoids are the
most common and hormonally active NETs. Their inci-
dence is estimated to be approximately 1.5–2.5 cases per
100 000 of the general population. They are usually slow-
ly growing neoplasms, and even when they exhibit
gross local invasion and/or metastases, they are charac-
terized by patients’ long survival and good general pro-
gnosis. However, metastases appearance and primary
tumour diameter above 2 cm worsen the prognosis and
limit the 5-year survival rate from 60–70% to 35%. They
frequently metastasize to the liver, regional lymph no-
des, and occasionally to the bones [1]. The most frequ-
ently encountered clinical presentations of carcinoids
are intermittent abdominal pain and carcinoid syndro-
me (diarrhoea, cutaneous flushing, valvular heart dise-
ase, bronchoconstriction, myopathy, and an increase in
skin pigmentation) when liver metastases occur. It sho-
uld be pointed out that carcinoid syndrome occurs in
less than 10% of patients with carcinoid tumours. Tre-
atment options for non-metastatic small carcinoid tu-
mours are endoscopic mucosal resection, minimally in-
vasive laparoscopic wedge resection, and classic surge-
ry. Surgery is the mainstay and the only potentially
curative therapy for carcinoid tumours. Treatment mo-
dalities for metastatic carcinoid tumours are orthotopic
liver transplant, hepatic artery embolisation, and long-
acting somatostatin analogues (octreotide, lanreotide),
adjuvant Indium-111, Yttrium-90, or Lutetium-177
octreotide-receptor targeted therapy [2, 3].
Case report and discussion
We report a case of a female patient suffering from
a carcinoid tumour with its primary focus in the ileum,
diagnosed at the age of 32 years (in 1979) with acute
appendicitis symptoms only. The carcinoid was diagno-
sed postoperatively by a histopathological assessment,
but neither Ki67, chromogranin A (CgA), synaptophy-
sin, neurone-specific enolase, nor somatostatin recep-
tor scintigraphy was assessed at that time. The tumour
was located in the ileum and infiltrated the appendix,
so the distal part of ileum and appendix were remo-
ved. After operation all symptoms were withdrawn.
A carcinoid is a hormonally active (serotonin secre-
ting) type of NET located in the small intestine. Most
NETs are located in a distal part of the jejunum and
ileum (23–38%). These tumours are characterized by
worse prognosis due to frequent often lymph nodes and
liver metastases [4]. When liver metastases arise, carci-
noid syndrome occurs. This is observed in 4-10% of all
carcinoid cases [4]. According to current guidelines,
immunohistological assessment is an important method
for NET diagnosis and prognosis, and for treatment
decisions, but in 1979 it was not routine in our country
[5, 6]. Patients without liver metastases are noted for lon-
ger 10-year survival rates than patients with metastases
present at diagnosis [6]. The diameter of the removed
tumour was greater than 10 cm and it suggested high
risk of metastases present at the time of surgery or ari-
sing in the close future, and worse prognosis [7].
The patient’s previous medical history was short.
When she was 20 years old she had suffered from paro-
xysmal tachycardia. At the age of 30 she had been ad-
ministered methimazole due to hyperthyroidism (au-
toimmune thyroid disease). Remission was achieved
after 6 months and L-thyroxine replacement therapy
had been started at a stable dose of 50 µg per day. Paro-
xysmal tachycardia was still present, but in lower fre-
quency. At the age of 55 an abnormal pathway ablation
was performed due to Wolff-Parkinson-White syndro-
me. At that time echocardiography did not reveal any
abnormal findings in the heart.
At the age of 57 there was evidence of nearly asymp-
tomatic numerous metastases. The patient was admit-
ted to a gynaecology department. Only intermittent
abdominal pain for about 1-2 years prior to diagnosis of
metastases was reported. Multiple metastases were lo-
cated in the parietal peritoneum, omentum, rectum, and
sigmoid colon (diameter 2–10 cm), a single tumour in
the urinary bladder bottom wall, and multiple bilateral
ovarian tumours (5–8 cm in diameter). Hysterectomy,
bilateral ovariectomy, omentum, and urinary bladder
wall tumour resection were performed. The patient was
admitted to the oncology department. The radiologist
reported in the first abdominal CT assessment of multi-
ple (above 10) liver hypodense lesions up to 4 cm in
diameter (Fig. 1). Carcinoid tumours were also detec-
ted by histological assessment in the lymph nodes, but
lymphadenopathy was not present. Small bowel carci-
Figure 1. Carcinoid hepatic metastases (CT scans, January 2004)
Rycina 1. Przerzuty rakowiaka do wątroby (badanie CT, styczeń
2004)
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noids are frequently multiple, exhibiting multicentrici-
ty in up to 30% of patients [8]. In our patient, some
metastases were removed and the total mass of the neo-
plasm was reduced. Small bowel carcinoids often give
metastases to the lymph nodes (39%) and to the liver
(31%), as in our patient [7]. Multiple peritoneum and
omentum metastases were probably due to carcinoid
cell spread during the primary focus resection in 1979.
The patient was not presenting typical signs or symp-
toms, but carcinoid syndrome is generally rare, mani-
festing in approximately 5–7% of patients. Younger pa-
tients are usually more likely to develop carcinoid syn-
drome, which worsens prognosis [7].
Chemotherapy was performed after partial carcinoid
metastases resection. The patient was given 6 times
doxorubicin (60 mg/m2) plus cyclophosphamide every
4 weeks and then 5 times leukovorin (L) plus 5-fluoro-
uracil (5-FU). CT after chemotherapy revealed no chan-
ges in comparison to the previous CT scan (stable dise-
ase — SD, according to RECIST criteria [9]). Due to su-
stained abdominal pain, gastrofibroscopy was perfor-
med and revealed multiple small mucous tumours in
the stomach. Mucous and submucous tissue samples
were taken and carcinoid was described in the histopa-
thology assessment. Due to our knowledge, it could be
carcinoid metastases or gastric NET type 1 tumour [10].
Three main types of enterochromaffin-like cells (ECL)
tumours, could be primary located in the stomach. The
most common, type 1, consist of an ECL, well-differen-
tiated cells, often recognized as multiple, multicentric,
small stomach tumours. It could be non-functioning or
serotonin-, gastrin- or rare ghrelin-producing, and in
these cases, “atypical” carcinoid syndrome could occur
[11]. The coexistence of two types of NETs (carcinoid
and type 1 gastric ECL cell tumour in this case) in one
patient is also possible [12]. Hypergastrinaemia is usu-
ally observed in type 1 gastric ECL cell tumours, but in
our patient hypergastrinaemia and chronic atrophic
gastritis was not present, so the gastric tumours were
probably carcinoid metastases.
After chemotherapy, as mentioned above, the pa-
tient was still nearly asymptomatic (moderate abdomi-
nal pain was present only) and tolerated chemothera-
py well. The subsequent 6 cycles of L and 5-FU plus
intravenous interferon alpha (dose unknown) were
administered into the hepatic artery. All cycles of che-
motherapy were ineffective. Chemotherapy using 5-FU,
streptozotocin, doxorubicin, and cyclophosphamide can
be a potent treatment tool, but only in poorly differen-
tiated neuroendocrine tumours with Ki67 above 2% or,
even better, above 15% [13]. Proliferation index was not
assessed in our patient. The long survival of the patient
following primary tumour resection suggests well-dif-
ferentiated carcinoid, but the lack of carcinoid syndro-
me symptoms gives rise to poorly differentiated neuro-
endocrine neoplasm. Chemotherapy was performed
based on the oncologist’s decision.
At the age of 60, the patient was admitted to the en-
docrinology department. She reported only mild to
moderate diarrhoea and abdominal pain which occur-
red sporadically. Physical examination revealed obesi-
ty (BMI 29.8 kg/m2) and hypertension (160/100 mm Hg).
The hypertension was not complicated. Laboratory as-
sessment showed optimal thyroid replacement (50 µg
of L-thyroxine per day). Thyroid ultrasound (US) was
normal. Abdominal US revealed multiple hepatic me-
tastases, mild hepatomegaly (13.5 cm), cholecystolithia-
sis, and celiac trunk region lymphadenopathy, which
were confirmed by CT (progression disease — PD, ac-
cording to RECIST criteria [9]). ECG was normal. The
laboratory results are given in Table I.
Serum bone specific alkaline phosphatase, 1,25-dihy-
droxy vitamin D, CEA, AFP, and other parameters were
normal. 111In-Octreoscan somatostatin receptor scintigra-
phy (SRS) revealed multiple lesions of increased radio-
activity in the liver and celiac lymph nodes. Unfortuna-
tely, when compared to CT scans and octreotide scinti-
graphy, not all the metastatic lesions had somatostatin
receptor expression. However, the patient was submit-
ted to 90Y-DOTATATE therapy. 111In-Octreoscan SRS be-
fore first dose of 90Y-DOTATATE therapy are shown on
Figures 2A and 2B. Radionuclide peptide receptor thera-
py is a novel and potent treatment in patients with NETs
and positive 111In-Octreoscan SRS [5–7, 11].
Table I. Pathological laboratory findings in a patient with carcinoid syndrome before 90Y-DOTATATE therapy
Tabela I. Nieprawidłowe wyniki badań laboratoryjnych u chorej z zespołem rakowiaka przed leczeniem 90Y-DOTATATE
Parameter Result Normal range
Fasting glucose [mmol/l] 5.62 3.3–5.5
120’ glucose after oral 75 g glucose tolerance test [mmol/l] 9.38 < 7.7
24 h urine serotonin [µg/24 h] 454.0 50.0–250.0
Chromogranin A (CgA) [nmol/l] 177.8 < 4.0
5-hydroxyindoloacetic acid (5-HIAA) [mg/24 h] 75.0 2.0–9.0
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Finally, because of cardiac insufficiency (NYHA IV),
cardiological therapy was prescribed: perindopril 5 mg/day,
bisoprolol 5 mg/day, and aspirin 75 mg/day. From Sep-
tember 2007 to April 2008, 3 cycles of 80 mCi 90Y-DOTA-
TATE were administered. The patient’s condition pro-
gressively and strongly worsened during the therapy.
The following symptoms appeared (Table II). In the la-
boratory assessment, only mild hyperbilirubinaemia
(2.1 mg/dl) and mild anaemia (drop from 13.0 g/dl to
11.5 g/dl) was observed. ECG revealed continuous atrial
fibrillation.
Just after the second 90Y-DOTATATE therapy, echo-
cardiography assessment revealed:
— serious combined tricuspid valve defect with pre-
dominant regurgitation (Fig. 3 and 4);
— moderate pulmonary valve regurgitation and pul-
monary hypertension;
— enlarged right atrium (area 32.8 cm2, LAD 40 mm)
and right ventricle (RVEDD 42 mm) (Fig. 3 and 4);
— mild increased inferior caval vein diameter (25 mm)
with decreased respiratory mobility (25/18 mm).
Chronic heart failure in the course of carcinoid he-
art syndrome was diagnosed and worsened the pa-
tient’s prognosis [15]. Serotonin, synthesized from the
amino acid tryptophan and released into the systemic
circulation, causes right-sided valvular heart disease
[16]. The chronic heart failure found in our patient was
due to right side valvular heart disease. The itching was
due to mild hyperbilirubinaemia or more probably due
to carcinoid peptides interacting with skin mastocytes.
Pruritus is one of the common skin symptoms of meta-
static neoplasm, especially serotonin positive (secreting)
neuroendocrine tumours [17]. The previously-observed
body mass increase was connected to retention of wa-
ter, muscle, and other soft tissues involution. A new
pharmacotherapy was applied: diuretics (furosemide
and spironolactone), bisoprolol, ramipril, digoxin, low
molecule heparin, gastric proton pump inhibitor, and
L-thyroxine. A cardiosurgeon disqualified the patient
from valve replacement surgery because of the high risk
Figure 2. 111In-Octreoscan SRS before first dose 90Y-DOTATATE therapy: carcinoid liver (SVII) metastases (A) and carcinoid peritoneum
metastases (B) are visible
Rycina 2. Scyntygrafia receptorów somatostatynowych za pomocą 111In-Octreosan przed pierwszą dawką 90Y-DOTATATE: widoczne
przerzuty rakowiaka do wątroby (SVII) (A) i otrzewnej (B)
A B
Table II. Patient’s signs and symptoms in March 2008
(according to NCI CTC toxicity scale)
Tabela II. Objawy podmiotowe i przedmiotowe
występujące u chorej w marcu 2008 roku (według skali
toksyczności NCI CTC)
Sign or symptom NCI CTC toxicity scale
Diarrhoea 3
Fatigue 3/4
Dyspnoea 4
Teleangiectasis 1
Abdominal pain 2
Tachycardia 2
Continuous atrial fibrillation 2
Hypertension 2
Cough 3
Nausea 2
Itching 3
Lower limb oedemas 3
Ascites 2
Anxiety 1
Depression syndrome 2
Weight loss 3
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of metastases progression when using an extracorpo-
real circulation device, high perioperative death risk,
and continuous anticoagulant therapy necessity with
high risk of metastases haemorrhage.
After the third cycle of 90Y-DOTATATE there was
no clinical improvement (Table III). Therapy was mo-
nitored by CgA concentration and abdominal CT scans.
CgA is one of the best markers of carcinoid activity and
total neoplasm mass [18]. The patient was disqualified
from the next 90Y-DOTATATE cycle. Short-acting octre-
otide analogue test showed good response, so long-ac-
ting octreotide (S-LAR) was applied in an increased dose
in April 2008. Somatostatin analogues are the first line
therapy for symptom remission of neuroendocrine tu-
mours and stabilize hormone production, and may have
an anti-proliferative action [3, 5–7, 14, 19].
Since August 2008 the patient has been treated with
30 mg dose of S-LAR. Her condition progressively im-
proved after 6 months of S-LAR therapy. Exercise dys-
pnoea (NYHA II), increased body weight, retention of
water, and mild itching were present. There was no
evidence of diarrhoea, cough, lower limb oedemas, or
tachycardia. Echocardiography and abdominal CT scans
did not change compared to previous exams. Low mole-
cule heparin was changed to ticlopidine due to gastric
disturbances with acetylsalicylic acid and difficulties in
maintaining therapeutic INR levels during the therapy.
The laboratory assessment is shown in Table IV.
In March 2009 there was a marked hormonal im-
provement — 24 hour urine serotonin was 54.2 µg (re-
ference range 50–250) and CT scans revealed partial
remission according to RECIST criteria [9] (Fig. 5). Unfor-
tunately, apart from the improvement, long-term pro-
gnosis for patients with carcinoid heart syndrome is
poor [20, 21].
We presented this case because the long-term su-
rvival is typical for carcinoids, but 30-years survival has
not been described in the literature yet.
Figure 3. Tricuspid valve of the patient with carcinoid syndrome:
cuspid fibrosis, rigid and shortening. Bicuspid valve is properly
open in diastolic. Right ventricle and right atrium dominance
according to left ventricle and atrium (apex, 4 caves projection)
Rycina 3. Zastawka trójdzielna chorej z zespołem rakowiaka:
Zwłóknienie zesztywnienie i skrócenie płatków. Zastawka mitralna:
prawidłowa czynność rozkurczowa. Prawe serce (komora i przed-
sionek) większe niż lewe (projekcja koniuszkowa czterojamowa)
Figure 4. Systolic phase. Tricuspid valve coaptation loss and
proper bicuspid valve coaptation
Rycina 4. Faza skurczowa. Niedomykalność zastawki trójdzielnej
i prawidłowa czynność zastawki mitralnej
Table III. Serum CgA concentrations in a patient with carcinoid syndrome during 90Y-DOTATATE therapy
Tabela III. Stężenie CgA w surowicy u chorej z zespołem rakowiaka w trakcie terapii 90Y-DOTATATE
Parameter 90Y-DOTATATE
Before After 1st cycle After 2nd cycle After 3rd cycle
CgA [nmol/l] (normal range < 4.0) 100.2 113.0 143.0 468.0
(60 min. after 100 µg
octreotide injection CgA — 391.0)
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